Rearrangement of the KMT2A gene is a recurrent mutation in acute myeloid leukemia (AML) that leads to poor outcomes in patients due to increased rate of relapsed and refractory disease. The identification of novel targets and potential therapies is crucial for patients with KMT2A-rearranged leukemias.

Immunoglobulin-like transcript 3 (ILT3, also...

TSC22 domain family member 3 (TSC22D3) is a glucocorticoid-induced gene that plays a key regulatory role in immunosuppression and cell proliferation. Its prognostic usefulness in acute myeloid leukemia (AML) has not been deeply investigated yet.

Rigel Pharmaceuticals Inc.’s ahead-of-deadline approval from the U.S. FDA of Rezlidhia (olutasidenib) twice-daily capsules for adults with relapsed/refractory (r/r) acute myeloid leukemia (AML) came as a surprise to the company, but followed encouraging interactions, “including a very positive midcycle review meeting,” said CEO Raul Rodriguez, adding that the firm will “redouble our efforts to make sure we're able to convey the information supporting this product” to the marketplace. Regulators had assigned the compound a Feb. 15, 2023, PDUFA date.

Umoja Biopharma Inc. and Nanjing Iaso Biotherapeutics Co. Ltd. have entered into a research agreement to evaluate Umoja's ICIL (induced cytotoxic innate lymphocytes) platform with Iaso's best-in-class chimeric antigen receptors (CARs).

Eterna Therapeutics Inc. has entered into a sponsored research agreement with a collaborator at The University of Texas MD Anderson Cancer Center (MD Anderson).

Maxinovel Pharmaceuticals Inc. raised ¥100 million ($13.8 million) in a series C+ round to develop its candidates for acute myeloid leukemia, solid tumors, and autoimmune diseases.